Figure 1. Sample patient selection. FP indicates fundus photography; OOI, other ocular imaging; and VF, visual field.
Figure 2. Visual field testing within 24 months of diagnosis among men and women of different races/ethnicities with incident open-angle glaucoma in 2003 and 2007.
Figure 3. Fundus photography within 24 months of diagnosis among men and women of different races/ethnicities with incident open-angle glaucoma in 2003 and 2007.
Figure 4. Other ocular imaging within 24 months of diagnosis among men and women of different races/ethnicities with incident open-angle glaucoma in 2003 and 2007.
Figure 5. Proportion of men and women of different races/ethnicities with incident open-angle glaucoma in 2003 and 2007 who underwent no ancillary glaucoma testing.
Figure 6. Probability of undergoing visual field testing for open-angle glaucoma from 2001-2009. AAM indicates Asian American men; AAW, Asian American women; BM, black men; BW, black women; HM, Hispanic men; HW, Hispanic women; WM, white men; and WW, white women.
Figure 7. Probability of undergoing fundus photography for open-angle glaucoma from 2001-2009. AAM indicates Asian American men; AAW, Asian American women; BM, black men; BW, black women; HM, Hispanic men; HW; Hispanic women; WM, white men; and WW, white women.
Figure 8. Probability of undergoing other ocular imaging for open-angle glaucoma from 2001-2009. AAM indicates Asian American men; AAW, Asian American women; BM, black men; BW, black women; HM, Hispanic men; HW; Hispanic women; WM, white men; and WW, white women.
Stein JD, Talwar N, LaVerne AM, Nan B, Lichter PR. Racial disparities in the use of ancillary testing to evaluate individuals with open-angle glaucoma. Arch Ophthalmol. 2012;130(8):doi:10.1001/archophthalmol.2012.1325.
eFigure 1. Probability of undergoing fundus photography for glaucoma suspects, 2001- 2009
eFigure 2. Probability of undergoing other ocular imaging for glaucoma suspects, 2001- 2009
eFigure 3. Probability of undergoing visual field testing for glaucoma suspects, 2001- 2009
Stein JD, Talwar N, LaVerne AM, Nan B, Lichter PR. Racial Disparities in the Use of Ancillary Testing to Evaluate Individuals With Open-Angle Glaucoma. Arch Ophthalmol. 2012;130(12):1579-1588. doi:10.1001/archophthalmol.2012.1325
SECTION EDITOR: PAUL P. LEE, MD
Author Affiliations: Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center (Drs Stein and Lichter and Mss Talwar and LaVerne); and Department of Biostatistics, School of Public Health (Dr Nan), University of Michigan, Ann Arbor.
Objective To determine whether racial disparities exist in the use of ancillary testing to evaluate individuals with open-angle glaucoma.
Methods We identified all enrollees aged 40 years and older in a large US managed care network with retinal or optic nerve conditions that could warrant the use of ancillary testing. Among persons with open-angle glaucoma or glaucoma suspects, we performed repeated-measures multivariable logistic regression to determine the odds and probabilities each year of undergoing visual field testing, fundus photography, and other ocular imaging for black, white, Hispanic, and Asian American men and women and compared the groups.
Results Among the 797 879 eligible enrollees, 149 018 individuals had open-angle glaucoma. The odds of undergoing visual field testing decreased for all groups from 2001 through 2009, decreasing most for Hispanic men and women (63% and 57%, respectively) (adjusted odds ratio [AOR], 0.37; 95% CI, 0.31-0.43 and AOR, 0.43; 95% CI, 0.37-0.50, respectively) and least (36%) for Asian American men (AOR, 0.64; 95% CI, 0.51-0.80). By comparison, the odds of undergoing other ocular imaging increased for all groups from 2001 through 2009, increasing most (173%) for black men and women (AOR, 2.73; 95% CI, 2.34-3.18 for men and AOR, 2.73; 95% CI, 2.40-3.09 for women) and least (77%) for Hispanic women (AOR, 1.77; 95% CI, 1.49-2.09).
Conclusion Hispanic men and women had considerably reduced odds of undergoing visual field testing and other ocular imaging compared with other groups during the decade. Although increases in glaucoma testing have been noted in recent years among Hispanic men and women for some types of ancillary tests, efforts should be made to better understand and overcome some of the persistent barriers to monitoring for glaucoma in this group.
Open-angle glaucoma (OAG) is a major cause of visual impairment, affecting more than 3 million individuals in the United States.1 With the aging of the US population, these numbers are expected to increase considerably in the coming decades. Because most patients with OAG are asymptomatic until rather late in the disease course and given that there are many effective medical and surgical treatments that can slow down or halt disease progression, it is imperative to identify and treat high-risk patients early in the course of the disease before they develop significant visual impairment. Numerous studies have found that OAG is more prevalent in racial minorities relative to the white population.2- 5 Other studies have shown that racial minorities are more likely to experience vision loss and blindness from OAG.6
Several studies indicated that disparities existed in glaucoma care in the 1990s. Two research groups have reported that black individuals were less likely to undergo examinations for glaucoma relative to white individuals.7,8 Using Medicare claims data from 1995 through 1999, Coleman and colleagues9 found that black and other individuals of nonwhite race had lower rates of undergoing visual field (VF) testing relative to white individuals in the year before glaucoma surgery. Other studies noted lower rates of medical and surgical treatment among racial minorities, despite the known higher incidence of OAG among these individuals.10 In January 2000, the US Department of Health and Human Services launched Healthy People 2010, a comprehensive program focused on disease prevention and health promotion. Reducing disparities in vision care, including care of individuals with OAG, was a specific focus of the Healthy People 2010 initiative.11
The purpose of our study is to assess whether disparities continue to exist in the monitoring of racial minorities with OAG and glaucoma suspects more than a decade since the launch of the Healthy People 2010 initiative; identify whether specific racial minority groups are affected more than others; and determine whether racial minorities are getting adequate exposure to technological advances in tests that monitor for glaucoma such as confocal scanning laser ophthalmoscopy, scanning laser polarimetry, and optical coherence tomography.
The i3 InVision Data Mart database (Ingenix) contains detailed fully de-identified records of all beneficiaries in a large, national managed care network in the United States. We had access to data for a subset of beneficiaries who had any form of eye care from January 1, 2001, through December 31, 2009. This subset consisted of beneficiaries who had 1 or more International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)12 codes for any eye-related diagnosis (code 360-379.9) or Current Procedural Terminology, Fourth Edition13 code for any eye-related visits, diagnostic or therapeutic procedures (code 65091-68899 or 92002-92499), or any other claims submitted by an ophthalmologist or optometrist during their time in the medical plan. For each beneficiary, we had access to all medical claims (ie, inpatient, outpatient, or skilled nursing facility) for ocular and nonocular conditions along with sociodemographic information (ie, age, sex, race/ethnicity, education level, and household net worth) for each enrollee.
All individuals aged 40 years and older who were in the database for 1 consecutive year or more and had 1 eye care provider or more (ophthalmologist or optometrist) visits during their time in the plan were identified. Individuals in the plan for less than 365 days and beneficiaries who were not in the plan continuously were excluded. Next, we identified those enrollees who had 1 or more diagnoses of conditions affecting the optic nerve (including different forms of glaucoma and other optic neuropathies) or retina (such as exudative macular degeneration and cystoid macular edema) that could warrant the use of ancillary testing (Figure 1). Next, ICD-9-CM diagnosis codes were used to identify individuals specifically diagnosed with OAG (codes 365.1, 365.10, 365.11, 365.12, and 365.15) and glaucoma suspects (codes 365.0, 365.00, 365.01, and 365.04). If a beneficiary was coded as a glaucoma suspect and as having OAG, they counted as a glaucoma suspect from the first glaucoma suspect diagnosis until they were first diagnosed with OAG, and they were counted as possessing OAG thereafter.
The race/ethnicity of each beneficiary was identified by the managed care company using information provided from 2 sources: public records (driver's license data) and E-Tech (Ethnic Technologies LLC), a tool that uses information from the name of the beneficiary and the census block he or she lives in to assign race/ethnicity. Enrollees were assigned to 1 mutually exclusive race/ethnicity: white, black, Hispanic, or Asian American. Previous comparisons between assignment of race/ethnicity using E-Tech and information collected from patient self-report demonstrated that E-Tech has a positive predictive value of 71% and the company reports an accuracy of properly identifying race of 96%.14,15
Statistical analyses were performed using SAS version 9.2 (SAS Institute). Participant characteristics were summarized for the sample using means and standard deviations for continuous variables and frequencies and percentages for categorical variables.
For this analysis, we identified 2 groups: patients with incident OAG diagnosed in 2003 and those diagnosed in 2007. To be considered to have incident OAG, a patient must have received no OAG diagnosis during a look-back period of 2 or more years (2001-2002 for the 2003 cohort and 2001-2006 for the 2007 cohort); had at least 1 OAG diagnosis during 2003 and 2007; and had at least 2 years of continuous coverage in the plan after OAG diagnosis. These 2 cohorts were followed up from their initial OAG diagnosis to determine the proportions undergoing 1 or more of each of the following tests: VF testing (Current Procedural Terminology, Fourth Edition codes 92081, 92082, and 92083), fundus photography (FP; code 92250), and other ocular imaging (OOI; code 92135) in the first 24 months following OAG diagnosis. Results of this analysis were stratified by race/ethnicity and also by each race/ethnicity and sex combination. χ2 Testing was performed to compare proportions undergoing ancillary glaucoma testing in the 2003 cohort and the 2007 cohort separately for each race/ethnicity and sex combination. A similar analysis was performed for glaucoma suspects.
For the next analysis, repeated-measures multivariable logistic regression was performed to compare the odds of undergoing VF testing, FP, and OOI for OAG during each year from 2001 through 2009 and these models were stratified by race/ethnicity and sex. The regression models were adjusted for age; education level; household net worth; region of residence; insurance plan type; type of eye care professional providing care (ophthalmologist only, optometrist only, or both provider types during their time in the plan); amount of time in the plan (by year); hypertension; hyperlipidemia; diabetes mellitus; obesity; and comorbid ocular conditions including those that would necessitate the use of these diagnostic tests such as cystoid and diabetic macular edema, exudative age-related macular degeneration, nonproliferative and proliferative diabetic retinopathy, other retinal conditions, and other conditions that can affect the optic nerve (ie, other forms of glaucoma and optic neuropathies). Preliminary analysis showed evidence of a quadratic trend in the use of these procedures hence, the effect of time was modeled as quadratic in the regression models. Furthermore, because this quadratic effect of time could have been different in the presence of different visual conditions, interactions were included between the effect of time and each of the following conditions: OAG, glaucoma suspect, macular edema, exudative macular degeneration, other retinal diseases, and other diseases of the optic nerve for the OOI and FP models as well as interactions between time and each of the following conditions: OAG, glaucoma suspect and other diseases of the optic nerve for the VF models. For white, black, Hispanic, and Asian men and women, we used the estimated model parameters to compare odds of receiving the relevant testing in 2001 vs 2005, 2005 vs 2009, and 2001 vs 2009 for an enrollee with OAG. A similar analysis was performed for glaucoma suspects. These odds were estimated assuming absence of other ocular conditions that could warrant the use of these tests and assuming an age of 60 years, commercial preferred provider organization insurance, northeast region of residence, exclusive care by an ophthalmologist, high school education, and a $75 000 to $150 000 household net worth. The estimated odds of receiving each procedure in each year were then converted to probabilities.
For all analyses, P < .05 was considered statistically significant. The University of Michigan's institutional review board determined this study was exempt from requiring its approval.
After using the inclusion and exclusion criteria, there were 797 879 individuals who were eligible for the OOI and FP models and 547 205 of these individuals were also eligible for inclusion in the VF model (Figure 1). Among the 797 879 enrollees who met the study eligibility requirements, there were 663 814 white, 51 638 black, 49 477 Hispanic, and 25 308 Asian American individuals; the remaining patients were of other or unspecified races/ethnicities. Of all the enrollees, 449 726 were women and 348 153 were men. The average (SD) age of those who were eligible was 57.1 (11.8) years and ranged from 53 to 58 years for the different races/ethnicities. The average (SD) length of time in the plan was 4.5 (2.2) years and ranged from 4.1 to 4.6 years for the different races/ethnicities.
Of the 797 879 enrollees, 149 018 (18.7%) had 1 or more diagnoses of OAG and 360 380 (45.2%) had 1 or more diagnoses of glaucoma suspect. The average age of persons with OAG was 61.3 years and for glaucoma suspects was 55.4 years. Among those with OAG, there were 118 062 white, 15 905 black, 9376 Hispanic, and 4350 Asian American individuals. Table 1 shows the other sociodemographic characteristics of the enrollees with OAG and glaucoma suspects.
The number of individuals with incident OAG with at least 24 months of follow-up in 2003 and 2007 were 4139 and 3803 persons, respectively. The proportions of white, black, Hispanic, and Asian American patients who underwent ancillary glaucoma testing within 24 months of their OAG diagnosis in 2003 were 74.5%, 73.8%, 65.5%, and 71.7% respectively for VF testing; 23.6%, 27.5%, 17.5%, and 20.0% respectively for FP; and 50.5%, 47.9%, 45.1%, and 48.3% respectively for OOI. By comparison, the proportions of white, black, Hispanic, and Asian American patients who underwent ancillary glaucoma testing within 24 months of their OAG diagnosis in 2007 were 75.8%, 73.7%, 72.8%, and 74.8% respectively for VF testing; 29.3%, 34.7%, 35.2%, and 35.8% respectively for FP; and 65.0%, 64.9%, 61.7%, and 66.2% respectively for OOI (Table 2 and
The proportion of white, black, Hispanic, and Asian American individuals with incident OAG diagnosed in 2003 who underwent no ancillary glaucoma testing (no VFs, FP, or OOI) within 24 months of diagnosis were 16%, 19%, 25%, and 21%, respectively. The proportion of white, black, Hispanic, and Asian American individuals with incident OAG diagnosed in 2007 who underwent no ancillary glaucoma testing (no VFs, FP, or OOI) within 24 months of diagnosis were 13%, 10%, 14%, and 15%, respectively (Figure 5). Table 3 shows the findings of similar analyses for glaucoma suspects.
Among men and women of all races/ethnicities with OAG, the odds of undergoing VF testing declined from 2001 to 2005 and again from 2005 to 2009. Comparing the odds of undergoing VF testing in 2001 vs 2009, Asian American men demonstrated the lowest decline (36%) in odds of receiving VF testing (adjusted odds ratio [AOR], 0.64; 95% CI, 0.51-0.80), while Hispanic men (63%) and Hispanic women (57%) experienced the greatest decline (AOR, 0.37; 95% CI, 0.31-0.43 for Hispanic men and AOR, 0.43; 95% CI, 0.37-0.50 for Hispanic women) in odds of undergoing VF testing (Table 4). Table 5 shows the findings for glaucoma suspects among the races/ethnicities.
No significant difference in the odds of undergoing FP were noted from 2001 to 2005 for most of the OAG groups with 2 exceptions: white women had 6% increased odds of FP and Asian American women had 72% increased odds of FP during that period. All of the groups beside Asian American women demonstrated increased odds of FP in 2009 relative to 2005. Overall, compared with 2001, these groups had significantly higher odds of FP in 2009: white men had 24% greater odds (AOR, 1.24; 95% CI, 1.16-1.32), white women had 15% greater odds (AOR, 1.15; 95% CI, 1.08-1.22), black women had 19% greater odds (AOR, 1.19; 95% CI, 1.03-1.38), Asian American men had 49% greater odds (AOR, 1.49; 95% CI, 1.09-2.03), and Asian American women had 86% greater odds (AOR, 1.86; 95% CI, 1.31-2.63) (Table 4). During that same time, the odds of FP for glaucoma suspects decreased for nearly all of the groups (Table 5).
The odds of undergoing OOI increased for men and women of each race with OAG from 2001 to 2005 and continued to increase for some of the groups from 2005 to 2009. Comparing the odds of OOI for OAG in 2001 vs 2009, the groups that demonstrated the greatest increase in odds of this procedure were black men (173%) and black women (173%), followed by Asian American women (157%), then white women (128%), Asian American men (127%), and white men (124%). Hispanic men (113%) and Hispanic women (77%) demonstrated the lowest increase in the odds of undergoing OOI in 2009 relative to 2001 (Table 4). Similar trends were observed for glaucoma suspects. In fact, unlike the other racial groups who demonstrated increased odds of OOI of 20% to 95% from 2001 to 2009, Hispanic men glaucoma suspects exhibited no significant difference in the odds of OOI in 2009 relative to 2001 (AOR, 1.12; 95% CI, 0.97-1.30) (Table 5).
In 2001, after adjustment for ocular comorbidities and other factors, the probability of undergoing VF testing for OAG was 61% for white men, 61% for white women, 66% for black men, 67% for black women, 63% for Hispanic men, 62% for Hispanic women, 64% for Asian American men, and 64% for Asian American women. By comparison, in 2009, the probability of undergoing VF testing for OAG was 45% for white men, 45% for white women, 53% for black men, 54% for black women, 39% for Hispanic men, 41% for Hispanic women, 54% for Asian American men, and 49% for Asian American women. The magnitude of decline in the probability of undergoing VF testing for OAG from 2001 to 2009 was most for Hispanic men (−24%) and Hispanic women (−21%). By comparison, black men (−13%), black women (−13%), and Asian American men (−10%) experienced a much reduced decline in the probability of undergoing VF testing for OAG during the decade (Figure 6). The change in probability of undergoing FP for OAG from 2001 to 2009 was quite minimal for all of the groups (range, +1% to +5%) (Figure 7). In 2001, the probability of undergoing OOI testing for OAG was 23% for white men, 23% for white women, 24% for black men, 23% for black women, 19% for Hispanic men, 22% for Hispanic women, 23% for Asian American men, and 21% for Asian American women. By comparison, in 2009, the probability of receiving OOI testing for OAG was 39% for white men, 41% for white women, 47% for black men, 45% for black women, 34% for Hispanic men, 34% for Hispanic women, 40% for Asian American men, and 41% for Asian American women. The magnitude of increase in probability of undergoing OOI for OAG from 2001 to 2009 was greatest for black men (+23%) and black women (+22%) and least for Hispanic men (+15%) and Hispanic women (+12%) (Figure 8). The probabilities of undergoing each ancillary test for glaucoma suspects of the different races/ethnicities are depicted in
Using longitudinal data from 149 018 enrollees with OAG in a large nationwide US managed care network, we explored rates of ancillary glaucoma testing for men and women of different races/ethnicities to determine whether differences exist in the evaluation and monitoring of OAG among minorities. We found significant differences in ancillary glaucoma testing among the groups. In 2009, black men and women with OAG had the highest odds of undergoing VF testing and OOI. Black men and women also demonstrated the largest increase in the odds of OOI and the least decline in the odds of VF testing during the decade relative to other groups. By comparison, Hispanic men and women had the lowest odds of VF testing and OOI in 2009 and exhibited the largest decline in the odds of undergoing VF testing coupled with the smallest increase in the odds of receiving OOI relative to the other groups during the course of the decade. Relatively similar trends were observed for glaucoma suspects.
During the past decade, Healthy People 2010 and several other initiatives have sought to reduce disparities in vision care provided to racial minorities in the United States. Prior to these initiatives, Coleman and colleagues9 noted that white individuals had a greater likelihood of undergoing VF testing in the year before surgery relative to black individuals and those of other races/ethnicities. In our analysis, we find that black individuals actually had the highest probability among all races/ethnicities, including white individuals, of undergoing VF testing in 2009. Furthermore, although the probability of undergoing VF testing has declined for all racial groups from 2001 through 2009, black men and women experienced less of a decline in the probability of undergoing these tests than did all other groups aside from Asian American men. It is encouraging to find that black individuals, a race known to have high rates of visual impairment and blindness from OAG, are undergoing ancillary glaucoma testing at higher rates relative to other racial groups than noted a decade earlier.
The specific factors contributing to higher probabilities of undergoing glaucoma testing among black individuals compared with white individuals noted in this study are unclear. Potential explanations for the greater use of ancillary glaucoma testing among black individuals include an increase in public service announcements educating the black population about OAG as well as improvements in the education of eye care providers about the increased risk for OAG and blindness from this disease among black individuals, which may impact practice patterns. Because disease severity can influence the frequency and intensity of glaucoma service use, the higher probabilities of undergoing testing among black individuals may be driven, in part, by the presence of more severe disease among black relative to white individuals on initial OAG diagnosis. Other studies have found evidence that black individuals tend to first present to eye care providers with more severe OAG compared with white individuals.3 Unfortunately, the current ICD-9-CM billing codes do not capture disease severity to study the influence of disease severity on patterns of ancillary glaucoma testing to determine whether this explains the differences in use we are noting, although in our analysis of glaucoma suspects, black men and women were also observed to have greater probabilities of ancillary glaucoma testing, suggesting that disease severity alone does not fully account for greater use among black individuals.
While it is encouraging that black individuals are receiving similar or greater levels of monitoring of OAG relative to white individuals, it is disconcerting that there are significant disparities in glaucoma testing among the Hispanic population, the fastest growing racial minority in the United States.16 Our finding that Hispanic individuals have lower probabilities of undergoing glaucoma testing relative to other races/ethnicities may be attributable, in part, to differences in rates of eye care visits among Hispanic people relative to other racial groups. Outside of the specialty of ophthalmology, studies have found that Hispanic individuals have reduced access to health care services and lower rates of use of medical services.17 Reduced frequency of visits and services among Hispanic individuals has also been demonstrated within the field of ophthalmology.18,19 Using data from the Los Angeles Latino Eye Study, Morales and colleagues19 found that only 36% of the participants aged 40 years or older (all of whom were Hispanic) underwent an eye examination in the past 12 months and only 57% admitted to ever receiving a dilated funduscopic examination. If Hispanic individuals with OAG are visiting eye care providers less often than are other racial groups, this is likely contributing to differences in the probability of undergoing glaucoma testing we observed. In the study by Morales and colleagues,19 some of the factors they found to be associated with a reduced likelihood of visiting an eye care provider among Hispanic people included younger age, male sex, less education, and lack of insurance. In our analysis, despite our adjusting for sociodemographic factors including age, education level, and household net worth and despite the fact that all of the enrollees had health insurance, we still observed lower probabilities of ancillary glaucoma testing among Hispanic men and women. Difficulty with the English language and lack of a usual eye care provider or usual place of care are all factors that affected rates of eye care visits among participants in the Los Angeles Latino Eye Study and may also be contributing to some of the trends we observed.19 Language barriers may be particularly problematic when performing VF testing on Hispanic individuals given the need to instruct patients on how to properly take this test.
Although our analyses demonstrated that Hispanic individuals are lagging behind those of other races/ethnicities with respect to monitoring for glaucoma, there is also some evidence that ancillary glaucoma testing among Hispanic individuals is catching up with testing for other races/ethnicities. The proportions of Hispanic individuals with newly diagnosed OAG in 2003 who underwent ancillary testing were much lower than each of the other races/ethnicities. However, the proportions of Hispanic people with newly diagnosed OAG in 2007 undergoing ancillary testing were much more similar to those of other races (Figures 2-5). Intensified efforts by groups such as EyeCare America to better educate the Hispanic population about the importance of regular eye care may be contributing to the reduction in disparities we are observing.
The strengths of this study include its large sample size, with adequate representation of each of the major racial groups. Furthermore, unlike other studies that review data collected at a specific academic medical center or from the practices of glaucoma specialists, the data for this analysis represents patients under the care of different eye care providers from communities throughout the United States. In addition, identification of enrollees with OAG and glaucoma suspects came from billing data from eye care providers, which may be more reliable than patient self-report.20
There are several study limitations that need to be acknowledged. Because the study was conducted using claims data, there is no way of verifying whether all of the enrollees indeed had OAG. Some of the patients may have been misdiagnosed or miscoded. Second, it is important to recognize that the race/ethnicity of some of the enrollees may have been misclassified. While E-Tech (the company that produces the software that was used to assign race/ethnicity to each enrollee) touts a 96% level of correspondence between its software and information obtained from patient self-report, this accuracy level has not, to our knowledge, been confirmed in a peer-reviewed publication. Furthermore, the E-Tech software does not further characterize Hispanic individuals as white or black. In a multiethnic population such as that of the United States, some enrollees may have been misclassified. Differential misclassification of individuals of different races/ethnicities as possessing OAG could affect our study findings. Third, with claims data, we were also unable to consider glaucoma severity, which could impact the frequency and intensity of monitoring. Without clinical information, it is impossible to determine for specific patients whether levels of testing for OAG were inadequate, appropriate, or excessive. Fourth, all of the enrollees in this database had some form of health insurance. Caution should be taken when generalizing our findings to other groups such as those who are uninsured or underinsured. Given that others have demonstrated that possessing health insurance impacts use of eye care services and that racial minorities are known to have reduced access to health insurance, it is likely that we are underestimating disparities in ancillary testing for glaucoma among racial minorities in the overall US population.21 In fact, recent US Census report data found that 1 in every 3 Hispanic individuals had no health insurance.22
It is encouraging that black individuals with OAG have higher rates of ancillary glaucoma testing compared with earlier studies. However, these findings need to be tempered by the fact that there are disproportionate numbers of black individuals and other racial minorities who are underinsured or uninsured and likely continue to have inadequate monitoring for OAG. Furthermore, we find disparities in monitoring for OAG among Hispanic men and women, even in this insured population. Future research must focus on identifying ways to reduce disparities in glaucoma care among racial minorities, especially the Hispanic population, the fastest growing racial minority in the United States.
Correspondence: Joshua D. Stein, MD, MS, University of Michigan W. K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, 1000 Wall St, Ann Arbor, MI 48105 (email@example.com).
Submitted for Publication: September 22, 2011; final revision received March 8, 2012; accepted March 13, 2012.
Author Contributions: All the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: The study was funded by K23 Mentored Clinician Scientist Award 1K23EY019511-01 from the National Eye Institute, a Clinician Scientist Grant from the American Glaucoma Society, a grant from the Blue Cross Blue Shield of Michigan Foundation, and an unrestricted grant from Research to Prevent Blindness.
Previous Presentations: This study was presented in part at the 2011 Association for Research in Vision and Ophthalmology Meeting; May 5, 2011; Ft Lauderdale, Florida, and the American Glaucoma Society Meeting; March 3, 2012; New York, New York.